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Non-suppressible parathyroid hormone secretion is related to gland
size in uremic secondary hyperparathyroidism. To determine the relative
importance of parathyroid gland enlargement and alterations in calcium
sensing (set-point changes) in the pathogenesis of uremic secondary
hyperparathyroidism (2°HPT), we investigated the relationship between
estimates of parathyroid gland size and calcium-mediated parathyroid
hormone (PTH) suppression in 19 normocalcemic 2"HPT patients on
chronic maintenance hcmodialysis. We compared our results to calcium-
mediated PTH suppression in 12 normal volunteers, 12 patients with
familial benign hypocalciuric hypercalcemia (FBHH), a disorder of ab-
normal calcium sensing, and 9 subjects with primary hyperparathyroidism
(1°HPT), which is characterized by both calcium set-point abnormalities
and parathyroid gland enlargement. We found that the 2°HPT group
displayed a distinctive pattern of calcium-mediated PTH suppression
characterized by a failure to normally suppress PTH at supraphysiologic
ionized calcium concentrations, similar to 1"HPT, hut without the right-
ward shift of the calcium-PTH suppression curve that characterizes
calcium sensing abnormalities in FBHH and l"HPT. In the patients with
2°HPT, hypercalcemic suppression resulted in an ending PTH (as a
percent of baseline) that was significantly higher (39.8 4.47%), and a
slope of the calcium-PTH suppression curve that was significantly less
negative (—4.8 0.53), compared to respective values of 19.4 1.81%
(P 0.0009) and —9.0 1.02 (P = 0.001) in normals and 19.1 2.49%(P = 0.001) and —9.6 1.11 (P = 0.0006) in FBHH. Values of ending
PTH and slope in 2°HPT patients, however, were similar to those found in
1HPT (49.8 6.35%, P = 0.21 and —4.5 0.74, P = 0.72). The ionized
calcium concentration required to attain half maximal PTH suppression
(EC50) in 2°HPT (1.20 0.02 mmol/liter) was not significantly different
from normals (1.25 0.01 mmol/liter, P = 0.12) hut was significantly less
than in 1"HPT (1.52 0.02 mmol/liter, P <0.0001) and in FBHH (1.44
0.02 mmol/liter, P < 0.0001). More importantly, we found a significant
linear correlation between the natural logarithm of gland size and ending
PTH suppression (r = 0.71, P < 0.001) and slope of the calcium-PTH
curve (r = 0.67, P = 0.002) in 2'HPT. Thus, calcium non-suppressible
PTH secretion in 2"HPT does not represent a simple set-point error, but
rather correlates with the degree of parathyroid gland enlargement.
Parathyroid gland dysfunction in uremic hyperparathyroidism
(2°HPT) is often resistant to therapy directed toward normaliza-
tion of the serum calcium, phosphorus and 1,25(OH), vitamin D
levels [1]. Refractoriness may be due to alterations in the calcium
sensing set-point and/or to increased functional parathyroid gland
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mass [2]. There are conflicting data regarding the relative contri-
bution of gland size and set-point abnormalities to non-suppress-
ible PTH in hemodialysis patients with secondary hyperparathy-
roidism. Many prior studies provide evidence for a calcium
sensing abnormality in a subset of patients with severe hyperpara-
thyroidism [3—7], but recent studies have failed to identify calcium
set-point abnormalities in normocalcemie dialysis patients with
2°HPT of different severity [8—101. Similarly, in spite of parathy-
roid gland enlargement, it has been difficult to conclusively show
that gland size is responsible for impaired calcium-mediated PTH
suppression in these patients. Whereas some studies have found a
relationship between basal circulating PTH concentrations and
parathyroid gland size [11—131, other investigations [7, 14, 15]
have not. The ability to show a role of parathyroid gland enlarge-
ment may be confounded by factors, such as use of PTH assays
that detect biologically inactive fragments, evaluation of non-
steady state PTH values due to variations in ambient serum
calcium concentrations or treatment with calcitriol, and/or the
variable presence of tertiary hyperparathyroidism. The dynamic
assessment of calcium-mediated PTH suppression in relation to
estimates of gland size might clarify the contribution of gland
mass to parathyroid dysfunction. The combined analysis of para-
thyroid gland function and size, however, has been performed
only in non-uremic renal transplant patients with persistent
hyperparathyroidism [7]. Though results from these hypercalce-
mic renal transplant patients indicate that residual gland mass can
contribute to persistent hyperparathyroidism, to date, no study
has directly determined the contribution of parathyroid gland
enlargement to impaired calcium-mediated PTH suppression in
dialysis patients with 2°HPT.
Many investigators have used both hypocalcemic stimulation
and hypercalcemie suppression to evaluate the entire sigmoidal
calcium-PTH curve [3, 5,8, 16]. Recently, we have shown that the
more limited calcium-mediated PTH suppression portion of the
curve can also he used to assess parathyroid gland function. Using
normals and subjects with familial benign hypocalciuric hypercal-
cemia (FBHH) and primary hyperparathyroidism (i°HPT), who
have known abnormalities of calcium sensing and gland size, we
derived parameters from the logarithmic transformation of the
calcium-PTH curve, that successfully predicted the relative con-
tribution of "set-point" abnormalities and gland enlargement to
PTH non-suppressibility [17]. In addition, high resolution ultra-
sound can reliably estimate parathyroid gland size in hemodialysis
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patients [11]. These findings suggest that current methods of
assessing parathyroid gland function and size can be used to study
the pathogenesis of 2°HPT.
In the current investigation, we directly tested the hypothesis
that parathyroid gland enlargement rather than a calcium sensing
defect causes resistance to calcium-mediated PTH suppression in
normocalcemic hemodialysis patients. We employed our model of
calcium-mediated PTH suppression and assessed parathyroid
gland size by high resolution ultrasound to evaluate the contribu-
tion of gland size and calcium "set-point" abnormalities in the
pathogenesis of 2°HPT in chronic hemodialysis patients. In
addition, we compared the results obtained in 2°HPT patients
with that of normal subjects, subjects with FBHH and 1°HPT. Our
results suggest that parathyroid gland enlargement rather than
calcium sensing abnormalities plays a predominant role in PTH
hypersecretion in patients with end-stage renal disease.
Methods
The data used in our analysis are part of databases gathered
from two independent studies, the main results of which have
been previously published [17, 18].
Subjects
We studied 19 chronic maintenance hemodialysis patients with
2°HPT [18]. None of these subjects had taken calcitriol or other
medications affecting bone and calcium metabolism for at least
three months prior to testing. Each patient was receiving 2500 mg
of elemental calcium (as calcium carbonate) each day in divided
doses with meals for the preceding four to six weeks. In addition,
as described earlier, we performed calcium-mediated PTH sup-
pression tests in 12 normal subjects, 12 subjects having FBHH,
and 9 having 1°HPT [17]. Other characteristics of the study
subjects have been previously published [17, 181.
Calcium-mediated PTH suppression tests
Calcium-mediated PTH suppression was assessed in the hemo-
dialysis patients with 2°HPT by dialysis against a solution contain-
ing 3.5 mEq/liter (1.75 mmol/liter) calcium. Blood for assay of
ionized calcium ([Ca2]) and intact PTH concentrations were
drawn at 0,2,5, 10, 20, 30, 60, 90, 120, 150 and 180 minutes, except
that three subjects had the test terminated at 120 minutes, and
seven terminated at 150 minutes. Calcium-mediated PTH sup-
pression was assessed in the normal, FBHH, and 1°HPT subjects
by intravenous administration of calcium gluconate at a rate of
0.025 mmol elemental calcium/kg for one hour, and then 0.05
mmol/kg for the second hour. Blood samples were drawn at —30,
—15, 0, 5, 10, 15, 30, 45, 60, 75, 90, 105 and 120 minutes. For the
present analysis, time 0 was used for the baseline values in all four
groups. We searched the literature to compare existing results of
calcium-mediated PTH suppression derived from these two dif-
ferent methods and found that they give similar suppression
curves [5, 6, 8, 19—24].
Assay methods
We measured [Ca2] at pH 7.40 using an ion-specific flow-
through electrode (Radiometer ICA, Copenhagen, Denmark).
Serum intact parathyroid hormone was measured by immunomet-
nc assays as previously described [17, 18]. For hemodialysis
patients, basal serum phosphorus was measured in the week of the
suppression test using autoanalyzer (Roche-Cobas Mira S, Mont-
clair, NJ, USA).
Assessment of parathyroid gland size
Patients with 2°HPT underwent parathyroid gland imaging to
estimate gland size [18]. This was done by high resolution
ultrasound in 15 subjects and magnetic resonance imaging (MRI)
in 3 (one subject refused imaging). All imaging studies were done
within two weeks of the suppression test, except for one study
done eight months after the suppression test. Because we previ-
ously showed no significant changes in parathyroid gland size over
time in this cohort [18], we used this value in our calculations.
Leaving this subject's data out of the analysis did not significantly
alter the results. Each visualized gland was measured at its
greatest dimension in three planes, anterior-posterior, medial-
lateral and superior-inferior. The resulting numbers (in cm) were
then simply multiplied together to get a standardized index of
gland size (in cm3). Results of these studies have been published
previously [18]. The reported accuracy, sensitivity and specificity
for detecting parathyroid enlargement are 91%, 73% and 98% for
high resolution ultrasound [25] and 90%, 78% and 95% for MRI
[26], respectively. In addition, parathyroid gland measurements by
high resolution ultrasound have been reported to correlate very
well with measurements of the gland size at parathyroidectomy
[111.
Data analysis
"PTH suppression" was expressed as the percent of basal PTH
level reached at any given [Ca2], that is, the lower the value, the
greater the suppression. We analyzed the association of calcium-
mediated PTH suppression with parathyroid gland size and EC50,
both by linear regression analysis and by dividing the subjects into
separate groups based on the degree of PTH suppression. We
defined normal suppressibility as values 32% of baseline PTH,
or 2 SD5 above the mean value reached at the end of the
suppression test in normal persons (19.4 12.5%). For analysis of
the relationship between PTH suppression and [Ca2] (Ca2 -
PTH relationship), the data were linearized by plotting the natural
logarithm (In) of the percentage of basal PTH against [Ca2] at
each time point for each subject in each group as previously
described [17]. A linear regression was performed for these
parameters for each subject, generating the regression equation:
In (% ofbasal PTH) = a + b1 * ionizedcalcium
and the slope of the Ca2-PTH relationship was defined as b1.
EC30 was defined as the [Ca2] at 50% of the maximal PTH
suppression [(100% + ending PTH% suppression)/2].
Statistical methods
We limited our analysis to the comparison of 2°HPT with the
other three groups. Statistical comparisons of FBI-IH and 1°HPT
with the normal group have previously been reported [171.
Because of differences in variances between the groups for some
of the variables, the groups were compared using the two tailed
Student's t-test where appropriate, instead of analysis of variance
[271. We controlled for multiple comparisons with the Bonferroni
adjustment. The groups were compared with respect to basal
[Ca2], ending {Ca2], range of the changes in [Ca2] ([Ca2]),
rate of the changes in [Ca2] concentration, basal PTH levels, end
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Fig. 1. Changes in serum ionized calcium concentration and intact PTH during calcium-mediated PTH suppression in normal subjects (Li) and patients with
FBHH ), 1°HPT (A) and 2°HPT (ti,). Hypercalcemia was induced in the chronic renal failure patients with 2°HPT by hemodialysis with a dialysate
solution containing 3.5 mEq/liter (1.75 mmol/liter) calcium. Calcium was elevated by calcium infusion in the other groups. A. Time dependent changes
in serum ionized calcium concentration. The rates of change in serum ionized calcium were similar in all groups and the range of these changes (
calcium) was significantly different only between 1°HPT and 2°HPT (P = 0.04; Table 1). B. Time dependent changes in serum intact PTH levels. Subjects
with FBHH displayed normal calcium mediated PTH suppression, whereas 1°HPT and 2°HPT patients showed significant degree of calcium
non-suppressible PTH Secretion. Ending PTH suppression, as percent of basal PTH, was similar in 1°HPT and 2°HPT (P = 0.21) whereas it was
significantly different between 2°HPT and both the normal and the FBHH group.
PTH suppression, EC50, and the slope. Simple linear regression
was used to analyze the relationship between gland size or the
natural logarithm of gland size [ln (gland size)], and the end PTH
suppression and the slope. We chose to use the logarithmic
transformation, because of the asymptotic relationship observed
when plotting gland size versus end PTH suppression or slope.
Additionally, we performed simple linear regression between both
the end PTH suppression and slope, and basal [Ca2], [Ca2],
maximal [Ca2], EC50, gland number as well as basal phosphate
concentration. We also performed multivariable regression anal-
ysis with the end PTH suppression or slope as the dependent
variable including the natural logarithm of gland size as well as
basal [Ca2 1 concentration and [Ca2I, as explanatory variables.
(Two models were tested for each dependent variable:
Dependent variable = a + b1 * ln(gland size) + b2 *
Dependent variable = a + b1 * ln(gland size) +
* [2+] + b3 *basal [2+])
All data are expressed as the mean SEM unless otherwise noted.
All statistical analyses were performed using SASTM (SAS Insti-
tute, Inc., Cary, NC, USA).
Results
Time-dependent changes in serum ionized calcium during calcium
loading
[Ca2] increased similarly as a function of time in all groups
during Ca2 loading, in spite of the differences in methods of
Ca2 administration (that is, high Ca2 dialysate in patients with
secondary hyperparathyroidism and Ca2 infusion in the other
patients) (Fig. IA). Moreover, [Ca2j following Ca2 loading
was not different between 2°HPT, normals and FBHH, but
slightly less in 1°HPT (Table 1). The average rate of change in
[Ca2] also was not significantly different between the 2°HPT
group (1.4 0.14 j.mol/liter/min) and the other groups (normals,
1.5 0.06; 1°HPT, 1.3 0.04; FBHH, 1.4 0.08 j.tmol/liter/min;
P> 0.5 for all comparisons). The EC50 for [Ca2] was also similar
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Table 1. Comparison of the calcium-mediated PTH suppression in 2°HPT with normal volunteers, 1°HPT and FBHH
Parameter
2°HPT(N 19) Normal(N = 12) 1°HPT(N = 9)
FBHH
(N = 12)
Basal intact PTH pg/mi 769 83.5 19 2.2 81 13 38 11
P = 0.0003 P = 0.0003 P = 0.0003
Basal [Ca2] mmol/liter 1.16 0.02 1.24 0.01 1.46 0.02 1.42 0.02
P = 0.009 P < 0.0001 P < 0.0001
Maximal [Ca2] mmol/liter 1.36 0.02 1.41 0.01 1.62 0.02 1.58 0.02
P = 0.07 P < 0.0001 P < 0.0001
[Ca2] mmol/liter 0.20 0.016 0.18 0.007 0.16 0.005 0.17 0.010
P= 0.12 P= 0.04 P= 0.15
End PTH % baseline 39.8 4.47 19.4 1.81
P = 0.0009
49.8 6.35
P = 0.21
19.1 2.49
P = 0.001
EC50 mmol/liter 1.20 0.02 1.25 0.01 1.52 0.02 1.44 0.02
P=0.12 P<0.0001 P<0.0001
Slope —4.83 0.53 —9.02 1.02 —4.49 0.74 —9.56 1.11
P = 0.001 P = 0.72 P = 0.0006
Values represent the mean SEM. All P values are for comparisons with the 2°HPT group, using Bonferroni correction for multiple comparisons.
in 2°HPT (1.20 0.02 mmol/liter) and normals (1.25 0.01
mmol/liter, P = 0.12). However, the EC5() in the FBHH and
1°HPT groups (1.44 0.02, and 1.52 0.02 mmol/liter, respec-
tively) were significantly greater than that observed in 2°HPT
(P < 0.0001 for both comparisons; Table 1).
Time-dependent changes in PTH during calcium loading
Basal PTH levels differed among the four groups (Table 1).
Basal PTH concentrations were highest in subjects with 2°HPT.
Basal PTH concentrations were also greater in 1°HPT than in
FBHH and normal subjects (that is, 1°HPT > FBHH> normals),
which was consistent with our previous findings [17]. To adjust for
differences in basal PTH values, we expressed PTH concentra-
tions for each group as a percentage of baseline values. Calcium
administration was sufficient to attain maximal PTH suppression
in normal, FBHH and the 2°HPT groups as evidenced by the
plateau of PTH after 90 minutes in normals and FBHH and after
120 minutes in the 2°HPT group, despite progressive increases in
[Ca2]. Though PTH suppression did not reach a definite plateau
in 1°HPT, the rate of PTH suppression had declined in these
patients, suggesting attainment of near maximal PTH suppres-
sion. The time-dependent suppression of PTH in response to
Ca2 was essentially identical in normal subjects and FBHH
patients (Fig. 1B), achieving respective PTH levels of 19.4
1.81% and 19.1 2.49% of basal values (Table 1). In contrast,
PTH was not normally suppressed by Ca2 in either the 1°HPT or
2°HPT groups (Fig. 1B). The 1°HPT and 2°HPT groups attained
end PTH levels of 39.8 4.47% and 49.8 6.35% of basal values,
respectively (P = 0.21).
Comparison of calcium-mediated PTH-suppression curves
To evaluate Ca2-mediated PTH suppression, we examined the
relationship between the natural logarithm of the percentage of
basal PTH and [Ca2J (Fig. 2). As we reported before, FBHH
patients with impaired Ca2 sensing had a rightward displacement
of the Ca2 -PTH relationship, but a normal slope (Fig. 2). This
pattern designates a "set-point" error with otherwise normal PTH
responses to increases in [Ca2I. The Ca2'-PTH relationship in
patients with 1°HPT was displaced to the right, consistent with a
"set-point" error, and had a significantly less negative slope,
correlating with increased parathyroid secretory mass [17J.
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Fig. 2. Relationship between PT!-! suppression and serum ionized calcium
concentration. PTH levels were expressed as natural logarithm of the
percent of baseline serum PTH concentration. Numbers indicate the
slopes of the respective lines. Each line represents the mean of the
individual subjects' curves. The slope in FBHH subjects (•) was similar to
normals (E; —9.6 and —9.0, respectively). In contrast, 1°HPT (A) and
2"HPT (A) had slopes (—4.5 and —4.8, respectively) that were significantly
different from normals. The rightward shift of the lines for FBHH and
l°HPT compared to the normal group is consistent with impaired calcium
sensing (that is.," set-point" changes), whereas the steepness of the slope
correlates with gland size abnormalities in 1°HPT and 2°HPT ([17] and
Table 2).
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Fig. 3. Relationships between ending serum PTH concentration and ionized
calcium in normal subjects (L) and patients with FBJ-IH •), 1°HPT (A)
and 2°HPT (A). The upper limit of normal for ending PTH suppression
(horizonal line) was defined as two SDS above the mean ending PTH
observed during calcium infusion in normal subjects as described in the
Methods section. Similarly, the upper limit for ending calcium (vertical
line) was defined as two SD5 above the mean ending calcium concentration
observed in normal subjects following calcium infusion. Four distinct
response patterns were observed: (1) left lower quadrant = normal, (2)
right lower quadrant = FBHH, (3) right upper quadrant = 1°HPT, (4) left
upper quadrant = 2°HPT with non-suppressible PTH. A subset of 2°HPT
patients had normal PTH suppression, whereas the majority failed to
suppress PTH at calcium concentrations sufficient to maximally suppress
PTH levels in normal subjects.
In contrast, the group with 2°HPT had a distinctive Ca2-PTH
relationship that differed from the others (Fig. 2). The Ca2-PTH
relationship in 2°HPT was characterized by an abnormal slope but
not a rightward shift, suggesting the absence of a simple "set-
point" error. The slope was significantly different in the 2°HPT
group compared to normals (—4.8 0.53 vs. —9.0 1.02
respectively, P = 0.001) and the FBHH group (—9.6 1.11, P =
0.0006), but similar to that observed in 1°HPT (—4.5 0.74, P =
0.97; Table 1 and Fig. 2). These findings suggest that the abnormal
Ca2-mediated suppression of PTH in urcmic 2°HPT is not due
to an abnormality of Ca2' sensing, but rather is related to gland
mass (see below).
Next, the relationship between PTH suppression and extracel-
lular [Ca2] was evaluated in individuals within each group. For
normal subjects, the upper limit for end PTH suppression in
response to hypercalcemia was defined as 32% of basal values
(horizontal line in Fig. 3; Methods) and the upper limit for ending
[Ca2j (similarly defined as 2 su above the mean) was 1.49
mmol!liter (vertical line in Fig. 3). Compared to normals, patients
with FBI-IH retained full PTH suppressibility, but at a higher
ending [Ca2'] as evidenced by the clustering of FBHH values in
the right lower quadrant (Fig. 3). Subjects with 1°HPT failed to
Dependent variables
Slope End PTH (% o
Independent variables r2 P value r2
f baseline)
P value
Simple linear regression
Gland size
ln(gland size)
Basal [Ca21
End[Ca ]
EC50
Basal phosphate
Multivariable regression
ln(gland size)[Ca2J
ln(gland size)[Ca2]
basal [Ca2]
0.33 0.01 0.41 0.004
0.45 0.002 0.50 0.001
0.03 0.48 0.24 0.04
0.02 0.53 0.0001 0.97
0.002 0.84 0.45 0.002
0.01 0.62 0.17 0.08
0.12 0.14 0.005 0.78
0.52 0.001
0.16
0.67 0.006
0.01
0.52 0.002
0.27
0.72
0.67 0.01
0.03
0.91
suppress PTH levels to the extent observed in normal and FBHH
subjects, as illustrated by the grouping of 1°HPT values in the
right upper quadrant (Fig. 3). There was a striking variability of
PTH suppression in 2°HPT patients in response to increments in
[Ca2j. The majority (11 of 19) failed to suppress PTH levels to
the extent noted in normals or FBHH, (mean end PTH, 54.0
3.4% of basal values; left upper quadrant, Fig. 3). This subgroup's
response resembled that in 1°HPT, except that the resistance to
Ca2-mediated PTH suppression which occurred at the end
[Ca2] was similar to that attained in normal subjects. The 8
remaining patients with 2°HPT attained ending PTH concentra-
tions that overlapped those of normals and FBHH (mean end
PTH 20.3 2.3% of basal values). We found no statistically
significant difference between the suppressible and non-suppress-
ible patients with regard to age, years on dialysis, basal PTH
levels, ending ionized calcium concentration or EC50 (data not
shown). There was a trend, however, towards longer duration of
dialysis in the group with less suppressibility, and patients with
abnormal PTH suppression had significantly larger parathyroid
glands (2.9 0.5 vs. 0.4 0.2 cm3, P = 0.001) and less negative
slope (—3.7 0.4 vs. —6.4 0.9, P = 0.009).
Role of parathyroid gland enlargement in calcium non-suppressible
PTH in chronic maintenance hemodialysis patients
To investigate variables associated with PTH suppression in
subjects with 2°HPT, we evaluated, by both simple linear and
multivariable regression analysis, factors that might contribute to
PTH suppression (Table 2). For analysis of PTH suppression,
both end PTH suppression (% of basal PTH) and slope of the
Ca2-PTH relationship were used as dependent variables. By
simple linear regression analysis, a strong linear relationship was
found between parathyroid gland size and the end PTH suppres-
sion (r2 = 0.41,P = 0.004; Table 2) as well as slope (r2 = 0.33,P =
0.01) in subjects with uremic 2°HPT (Table 2). Logarithmic
A
Table 2. Simple and multivariable regression between Ca2-mediated
PTH suppression and various parameters in 19 chronic maintenance
hemodialysis patients
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Simple linear regression shows that gland size and ln(gland size) were
- significantly correlated with slope and end PTH (expressed as percent of
baseline level). Basal and [Ca2] also correlate with end PTH, but not
1 8 slope. Multivariable regression analysis shows that only ln(gland size)
correlates independently with slope. [Ca21 and ln(gland size) were
independent predictors of end PTH suppression.
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transformation of parathyroid gland size [ln(gland size)] resulted
in an even stronger association (r2 = 0.50, p = 0.001 for end PTH
suppression and r2 = 0.45, P = 0.002 for slope; Table 2 and Fig.
4). Neither basal [Ca2], [Ca2], ending [Ca2], EC50 or basal
serum phosphate concentration correlated with the slope (Table
2). In contrast, basal [Ca2 I and [Ca2 ,but not ending [Ca2]
or EC)(J showed significant linear relationship with end PTH
suppression on simple linear regression (Table 2). We also found
a significant relationship between slope and end PTH suppression
(r2 = 0.47, P = 0.001). In addition, we found that the number of
glands detected in each patient showed borderline significant
association with end PTH suppression (r2 = 0.18, P = 0.07) and
slope (r2 = 0.29, P = 0.02), but total gland volume showed
stronger correlation with both variables.
Multivariable regression analysis was used to explore if other
parameters altered the observed relationship between slope and
ln(gland size). We included basal [Ca2] and [Ca2 ' in our
model, because these variables showed significant relationships
with end PTH suppression by simple linear regression (Table 2).
However, adding these variables to the model did not alter this
relationship or significantly improve the predictability of slope. In
contrast, using end PTH suppression as the dependent variable,
we found that the inclusion of [Ca2] in addition to ln(gland
size), provided the best model to explain the variability in end
PTH suppression. The ln(gland size) continued to be significantly
associated with the % PTH suppressibility when controlled for
[Ca2] alone (P = 0.006) or both [Ca2] and basal [Ca2] (P =
0.01; Table 2).
Discussion
The most important finding of our current analysis is the strong
association between parathyroid gland size and calcium-mediated
PTH suppression (Fig. 4; Table 2). Our studies also compare
Ca2-mediated PTH suppression in uremic 2°HPT with that of
patients with 1°HPT and FBHH (Fig. 2; Table 1). FBHH is a
disorder of calcium sensing due to mutations of the calcium
receptor (CaR) [28, 29], and 1°HPT is characterized by both
alterations in calcium sensing and variable increases in adenoma
size [171. FBHH is characterized by a predominant "set-point"
abnormality that is manifested by a rightward shift and normal
slope of Ca2-PTH relationship (Fig. 2). 1"HPT is characterized
by both a "set-point" error (that is, rightward shift of the curve)
and increased gland mass (that is, decreased slope of the Ca2 -
PTH relationship; Fig. 2) [17]. By comparing uremie 2°HPT to
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Fig. 4. Relationships between parathyroid gland size and calcium-mediated PTH suppression. Simple linear regression between ln(gland size) and slope
of the calcium-PTH curve (A), and between ln(gland size) and the ending PTH suppression (B). Resistance to calcium-mediated PTH suppression as
assessed by either slope or ending PTH correlated with gland size (r = 67, P = 0.002 and r = 0.71, P = 0.001, respectively).
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these non-uremic disorders that have characteristic abnormalities
of parathyroid gland function, we have separately assessed the
contribution of "set-point" and gland size to the genesis of
2°HPT. Our new finding is that patients with 2°HPT have a
pattern of Ca2tmediated PTH suppression differing from that
observed in normal, 1°l-IPT, and FBHH subjects. 2°HPT was
characterized by a reduction in slope but without a rightward shift
in the Ca2-PTH relationship (Fig. 2). Thus, unlike the situation
in 1°HPT and FBHH, set-point abnormalities appear not to
account for excess PTH secretion in uremic 2°HPT, at least in
normocalcemic patients on chronic maintenance hemodialysis.
Our studies provide direct information about parathyroid gland
size (estimated by high resolution ultrasound) and its relationship
to in vivo dynamic testing of parathyroid function in normocalce-
mic chronic maintenance hemodialysis patients. The predominant
role of gland size in non-suppressible PTH secretion is supported
by several findings. First, the abnormal slope of the Ca2 '-PTH
suppression curve was directly correlated with gland size in
2°HPT (that is, the greater the gland size, the less negative the
slope; Fig. 4A). These results are similar to our previous findings
that the slope of Ca2-PTH relationship correlated with tumor
mass in l°HPT [17]. Second, decreased maximal PTH suppression
in response to elevated serum [Ca2 ] also showed strong associ-
ation with parathyroid gland size in uremic 2°HPT (Fig. 4B). Most
importantly, independent effects of gland size on PTH suppress-
ibility were evident even when differences in basal [Ca2] and
[Ca2] were considered in multivariable regression analysis
(Table 2). Finally, by using the range of PTH suppression in
normal volunteers, we separated the uremic subjects into those
that suppressed PTH normally (that is, to values 32% of basal
PTH) and those with abnormal PTH suppression in response to
increased [Ca2] (Fig. 3). This analysis also supported a role for
parathyroid gland enlargement in the observed PTH non-sup-
pressibility, since abnormal suppression was associated with larger
parathyroid glands. A role of gland size is consistent with the
notion of a calcium independent non-suppressible component of
PTH secretion [30] and by the ability to induce PTH-mediated
hypercalcemia by transplanting several normal parathyroid glands
into normal animals [31].
In prior studies it has been difficult to consistently demonstrate
an association between gland size and PTH levels [7, 11—15].
These inconsistent findings might be attributed to use of PTH
assays that recognized circulating inactive PTH fragments, differ-
ences in the presence of autonomous parathyroid gland function
(that is, tertiary hyperparathyroidism), and concurrent treatment
with calcitriol that might he expected to alter the relationship
between parathyroid gland function and size. Our study more
firmly establishes the role of gland size in the pathogenesis of
secondary hyperparathyroidism. Indeed, our findings give direct
evidence in support of prior predictions [32, 33] that parathyroid
gland enlargement or some factor associated with enlargement,
such as genetic deletions, causes resistance to calcium-mediated
PTH suppression in patients with end-stage renal disease. In
addition, our results have significant implications for management
of patients with secondary hyperparathyroidism and highlight the
importance of preventing glandular enlargement in the treatment
of hyperparathyroidism.
Our studies should be viewed in the light of potential differ-
ences in the calcium suppression test used in the subjects with
2°HPT compared to the other groups. We do not believe,
however, that these potential protocol differences compromise
our conclusions. First, the strong association between gland size
and PTH suppressibility is not dependent on comparisons be-
tween different protocols. Second, [Ca2] is by far the most
important regulator of PTH secretion [22] and in our studies, both
protocols (that is, dialysis against high dialysate calcium and
calcium infusion) resulted in similar kinetics of serum calcium
elevations and PTH suppression (Fig. 1). Moreover, evidence
from in vitro experiments as well as clinical studies, indicate that
individual factors that may affect PTH secretion during dialysis
(such as changes in phosphorus, magnesium, glucose, pH and
osmolality [8]), have little effect in the acute setting [22, 34—38].
Finally, from the analysis of existing data it appears that the
suppression curves generated by both methods are similar [5,6, 8,
19—24]. Indeed, the calculated slope in our dialysis patients is
consistent with the slope derived from calcium infusion protocols
[8, 24].
Our results may not preclude the presence of set-point abnor-
malities in other uremic patients, particularly hyperparathyroid
patients with tertiary and/or severe hyperparathyroidism, as de-
scribed by Felsenfeld et al [6] and Malberti et al [5]. Indeed, in
vitro studies of isolated parathyroid cells [3, 4], and dynamic
testing of parathyroid function in hypercalcemic dialysis patients
[5, 6, 39] suggest that hypercalcemic patients (that is, with tertiary
hyperparathyroidism) have a set-point abnormality similar to that
observed in 1'HPT. The evolution of 2°HPT to tertiary hyper-
parathyroidism, therefore, may represent the occurrence of clonal
transformation of parathyroid cells that impart a defect in calcium
sensing leading to hypercalcemia [40—42]. In support of this
notion are recent studies showing decrease in the calcium recep-
tor in parathyroid glands of uremic patients undergoing parathy-
roidectomy [43]. Though our study did not examine set-point
abnormalities in hypercalcemic dialysis patients, we predict that
calcium-mediated PTH suppression in dialysis patients with ter-
tiary hyperparathyroidism might resemble that of 1°HPT (that is,
displaying both a rigthward shift corresponding to a "set-point"
abnormality and decreased slope due to increased gland mass).
It is also possible that our global assessment of parathyroid
function may not have detected subclinical set-point abnormalities
in individual glands. In fact, the in vitro assessment of parathyroid
glands isolated from the same patient can display a wide range of
set-points [3]. Typically, however, the presence of abnormal
calcium sensing leads to a hypercalcemic phenotype. Moreover,
we have shown that the presence of a set-point abnormality can be
detected by our calcium-mediated PTH suppression protocol. In
primary hyperparathyroidism, for instance, calcium infusion can
detect calcium set-point abnormalities even in the smallest ade-
noma, in spite of the presence of normal calcium sensing in
non-affected parathyroid tissue [17].
In summary, we did not detect a calcium sensing abnormality
(that is, "set-point" changes) in our subjects with 2°HPT. Instead,
our dialysis patients exhibited marked variation in PTH suppres-
sion and a decrease in the slope of the log-linear relationship
between percent PTH suppression and serum [Ca2]. The abnor-
mal PTH suppression and slope is similar to the abnormalities
observed in patients with 1°HPT and these parameters are
strongly associated with parathyroid gland size in 2°HPT. The
relationship between gland size and the inability to suppress PTH
levels suggest that hyperplasia of the parathyroid glands may be
1670 Indridason et al: Gland size and PTH secretion in 2'HPT
the predominant factor in the genesis of 2°HPT in normocalcemic
hemodialysis patients.
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